2015
DOI: 10.1093/annonc/mdv052.01
|View full text |Cite
|
Sign up to set email alerts
|

Chemotherapy of Malignant Pleural Mesothelioma Does not Preclude Use of Check-Point Blockade

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Binding of ICOS-L to OPN, instead promoted tumor metastases in a mouse breast cancer model (85). ICOS-L is expressed also in human malignant mesothelioma (87). Thus, also for this new molecular partner of OPN, interfering with this binding may be explored as a new therapeutic approach.…”
Section: Icos a Costimulatory Receptor Expressed On Activated T (86)mentioning
confidence: 99%
“…Binding of ICOS-L to OPN, instead promoted tumor metastases in a mouse breast cancer model (85). ICOS-L is expressed also in human malignant mesothelioma (87). Thus, also for this new molecular partner of OPN, interfering with this binding may be explored as a new therapeutic approach.…”
Section: Icos a Costimulatory Receptor Expressed On Activated T (86)mentioning
confidence: 99%